GMAB News and Press, Genmab A/S From 06/09/22

Genmab is one of my top picks in healthcare. The company expects to report impressive growth over the remainder of 2022 and beyond. Genmab has an imposing pipeline of proprietary and partnered programs that should provide additional growth opportunities. Genmab recently publicized...

Danish biotech firm Genmab A/S (GMAB) said on Thursday it had begun a new arbitration and was seeking an award of $405M under its license agreement with Johnson & Johnson's (JNJ) unit Janssen Biotech for cancer drug, Darzalex. Genmab is locked in a legal battle with JNJ ove...

-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to be presented in an oral session -- -- Additional poster presentati...

-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to be presented in an oral session -- -- Additional poster presentati...

Multiple epcoritamab (DuoBody ® -CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line combination study in patients with recurrent or metastatic cervical ca...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (NYSE: JNJ ) stock is up for 2022 in a down market Credit goes to its medical devices and anti-cancer drug Darzalex JNJ’s dividend has been rising for six decades, making it a safe st...

Multiple epcoritamab (DuoBody ® -CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several abstracts evaluating Genmab owned and partnered programs accepted for pr...

The following slide deck was published by Genmab A/S in conjunction with their 2022 Q1 earnings call. For further details see: Genmab A/S 2022 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2022 Earnings Call May 11, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript

Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bern...